Is Edgewise Therapeutics (EWTX) Undervalued As Its HFpEF Phase 2 Trial Begins?
Edgewise Therapeutics (EWTX) has advanced its cardiovascular efforts by dosing the first patient in EQUINOX-HFpEF, a Phase 2 trial of oral cardiac sarcomere modulator EDG-15400 in adults with HFpEF.
Against this clinical backdrop, Edgewise Therapeutics has seen a mixed share price pattern, with the stock down 17.03% on a 1 month share price return and 6.44% over 7 days, yet still showing a 55.87% year to date share price return and a 1 year total shareholder return of 137%. This points to strong longer term momentum despite recent pullbacks, as investors weigh fresh cardiovascular progress against prior gains.
Scan beyond Edgewise Therapeutics and compare this trial-driven momentum with other biopharma opportunities using our curated list of 20 high quality undiscovered gems.
Edgewise Therapeutics now has a richer pipeline story and a share price that has already moved hard. The real question is whether that clinical ambition is already fully reflected in today’s US$37.02 price.
Most Popular Narrative: 28% Undervalued
Against the last close at $37.02, the most followed narrative puts Edgewise Therapeutics at a fair value of $51.69, using a 7.24% discount rate to connect today’s loss making reality with potential future earnings power. That gap is built on a view that the cardiovascular pipeline and Servier deal together could justify a much richer valuation if things go right.
Completion of the sale of sevasemten and the muscular dystrophy platform to Servier for US$1.55b upfront plus up to US$1.1b in milestones frees Edgewise Therapeutics to concentrate capital and management attention on cardiovascular assets. This could influence future revenue growth and reduce funding pressure on earnings.
See why 1 investors see Edgewise Therapeutics as 28% undervalued.
Result: Fair Value of $51.69 (UNDERVALUED)
Still, the Edgewise Therapeutics story can change quickly if EDG-7500 stumbles in later trials or if sustained losses of around US$49.0 million a quarter continue.
Find out about the key risks to this Edgewise Therapeutics narrative.
Next Steps
Mixed signals around Edgewise Therapeutics can feel confusing, so move quickly from headline noise to your own verdict by weighing the 1 key reward and 3 important warning signs.
Looking for more Edgewise Therapeutics sized ideas?
Do not stop with Edgewise Therapeutics. Put today’s insights to work by lining up fresh prospects that fit your return goals and risk comfort before the market moves on.
- Target potential upside in quality companies that trade below their estimated worth by scanning through our 32 high quality undervalued stocks.
- Prioritise resilience and sleep-at-night balance sheets using the focused list of solid balance sheet and fundamentals (25 results).
- Limit unpleasant surprises by concentrating on businesses with steadier profiles through our 32 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com